Morganville, NJ, United States of America

Alexei Kalinin

USPTO Granted Patents = 10 



Average Co-Inventor Count = 5.8

ph-index = 4

Forward Citations = 64(Granted Patents)


Location History:

  • Kingston, CA (2004 - 2005)
  • Springfield, MO (US) (2007 - 2011)
  • Morganville, NJ (US) (2019 - 2023)

Company Filing History:


Years Active: 2004-2024

Loading Chart...
Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: Inventor Alexei Kalinin: Pioneering Beta-3 Agonists

Introduction

Alexei Kalinin, an innovative inventor located in Morganville, NJ, is known for his significant contributions in the field of pharmaceutical research. With a total of six patents to his name, Kalinin focuses on the preparation of beta-3 agonists, which play a crucial role in various therapeutic applications. His work exemplifies the intersection of science and innovation in addressing complex medical needs.

Latest Patents

Kalinin's latest patents detail a groundbreaking process for preparing beta-3 agonists and intermediates. These patents emphasize the use of ketoreductase (KRED) biocatalyst enzymes as part of efficient and economical processes. The formulations and methods outlined in these patents not only highlight the preparation of beta-3 agonists but also offer insights into intermediate compounds that can facilitate their synthesis. This innovative approach could make significant strides in drug development.

Career Highlights

Kalinin is currently a pivotal member of the Merck Sharp & Dohme Corporation, a leading pharmaceutical company where he applies his expertise in biocatalysis and pharmaceutical processes. His work is characterized by a commitment to advancing drug development through innovative methods that prioritize efficiency and effectiveness in pharmaceutical production.

Collaborations

Throughout his career, Kalinin has collaborated with notable colleagues, including Zhuqing Liu and Feng Xu. These collaborations reflect a synergy of ideas and expertise that contribute to the innovative processes being developed at Merck Sharp & Dohme Corporation, pushing the boundaries of what is possible in pharmaceutical science.

Conclusion

Alexei Kalinin stands out as a prominent inventor whose work in developing beta-3 agonists has the potential to make significant impacts in the field of medicine. With a focus on innovative processes and collaboration, he continues to contribute valuable advancements that address critical healthcare needs. As pharmaceutical science evolves, inventors like Kalinin play an essential role in shaping the future of drug development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…